Home Blog Page 226
Telomeric DNA is subject to attrition due to aging
Telomere length hasn’t been a reliable yardstick for measuring the progress of cancer. Because cancer cells divide frequently, and because telomeres shorten with repeated cell division, you might expect cancer cells to age rapidly, and then expire. Yet cancer cells often compensate by making more telomerase enzyme, which prevents the telomeres from getting even shorter. All the same, many...

The May issue of Clinical OMICs is available now! Check it out by clicking on the link below.

Source: © Monkey Business/Fotolia
Promising to bring the benefits of genetic testing to every woman and man, Color Genomics said yesterday it was launching with $15 million in financing, and an immediately-available $249 test for genes linked to breast and ovarian cancers. The company’s Color Test is designed to analyze mutations in the 19 genes known to be responsible for an inherited predisposition to...
Foundation Medicine announces its collaboration with the National Cancer Institute study to further understand the molecular underpinnings that may lead to exceptional responses for drug therapies in patients with cancer. [jessicaphoto/iStock]
The Massachusetts based Foundation Medicine, which develops, manufactures, and sells genomic analysis diagnostics for solid and circulating cancers has announced a collaboration with the National Cancer Institute (NCI) on the Exceptional Responders Initiative (ERI). The alliance is for an exploratory study to investigate the unique molecular indicators of tumors associated with cancer patients with excellent prognosis to drug therapies. The...
Source: © Tyler Olson/shutterstock
Scientists at the Ohio State University Comprehensive Cancer Center have developed a new method for measuring genetic variability within a tumor that might one day help doctors identify patients with aggressive cancers that are more likely to resist therapy. Researchers used a new scoring technique they developed called MATH (mutant-allele tumor heterogeneity) to measure the genetic variability among cancer cells...
Source: iStock/© AlexRaths
Roche’s Ventana Medical Systems said today it has inked a master collaboration agreement with Astellas Pharma to develop new automated tissue diagnostics to support therapeutic compounds in development. The value of the collaboration was not disclosed. Initial projects related to the collaboration will center on creating a diagnostic test intended to support early-stage clinical trials for Astellas’ Phase I cancer...
Source: © Jaimie Duplass/Fotolia
Roche acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance technology development for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) in blood. CAPP Medical's technology is designed to isolate and quantify small amounts of ctDNA through a simple blood draw, which has the potential to be...
Source: iStock/© AlexRaths
Rosetta Genomics said today it has agreed to acquire CynoGen, which does business as PersonalizeDx, from Prelude, in a purchase that expands the buyer’s presence and product offerings in oncology diagnostics. The acquisition will also create a combined pipeline for Rosetta Genomics that is set to introduce to market five new assays within the next 12 months. One of them...
Source: iStock/© ValuaVitaly
Researchers report that the Harmony prenatal test by Ariosa Diagnostics undertaken between 10 to 14 weeks of pregnancy may be more effective in diagnosing Down syndrome and two other less common chromosomal abnormalities than standard noninvasive screening techniques. In the study (“Cell-free DNA Analysis for Noninvasive Examination of Trisomy”) published in the New England Journal of Medicine, which followed pregnancy...
Cynvenio Biosystems developed LiquidBiopsy
Cynvenio Biosystems, with its LiquidBiopsy® rare cell isolation and genomic analysis platform, is at the forefront of cancer diagnostics. Rather than rely on tissue biopsies or counting circulating tumor cells in the blood, this technology extracts and sequences those cells’ DNA. That, in turn, makes possible real-time analysis of specific alterations within tumors that affect treatment decisions. Historically, blood draws...
Scroll Up